Source:http://linkedlifedata.com/resource/lhgdn/association:4005
| Subject | Predicate | Object | Context |
|---|---|---|---|
| lhgdn:association:4005 | lhgdn:found_in | pubmed-article:17145843 | lld:lhgdn |
| lhgdn:association:4005 | lhgdn:geneRifSource | In contrast with CLL, the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy. | lld:lhgdn |
| lhgdn:association:4005 | lhgdn:mesh_code | D019337 | lld:lhgdn |
| lhgdn:association:4005 | lhgdn:associationIdType | http://bio2rdf.org/euadr:Al... | lld:lhgdn |
| lhgdn:association:4005 | lhgdn:umls_code | umls-concept:C0376545 | lld:mappings |
| entrez-gene:1043 | lhgdn:associationId | lhgdn:association:4005 | lld:lhgdn |